Compare VIK & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VIK | INSM |
|---|---|---|
| Founded | 1997 | 1988 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.3B | 30.1B |
| IPO Year | 2023 | 2000 |
| Metric | VIK | INSM |
|---|---|---|
| Price | $68.50 | $145.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 24 |
| Target Price | $79.25 | ★ $198.04 |
| AVG Volume (30 Days) | ★ 2.7M | 1.9M |
| Earning Date | 03-03-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.45 | $174.73 |
| Revenue Next Year | $14.11 | $65.13 |
| P/E Ratio | $37.68 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $31.79 | $60.40 |
| 52 Week High | $81.48 | $212.75 |
| Indicator | VIK | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 42.56 | 48.49 |
| Support Level | $67.37 | $142.99 |
| Resistance Level | $68.60 | $149.08 |
| Average True Range (ATR) | 2.54 | 5.27 |
| MACD | -0.06 | 1.07 |
| Stochastic Oscillator | 10.57 | 65.62 |
Viking Holdings Ltd is a travel company, with a fleet of 92 small ships, which view as floating hotels. It offers travel experiences on all seven continents in all three categories of the cruise industry river, ocean, and expedition cruising. The Group defines its products based on the type of cruise offering and language of the cruise service. The River segment provides river cruises outside the United States to English-speaking passengers. The Ocean segment offers ocean cruises to English-speaking passengers. Other include operating segments that are not individually reportable, consisting of expedition cruises for English-speaking passengers (Expedition), Mississippi River cruises for English-speaking passengers, and Viking China, which includes cruises for Mandarin.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.